ECKERT & ZIEGLER BG 
By Regulated Information
Third Quarter 2012 Results
Seneffe, Belgium, November 6, 2012, Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB), a global leader in brachytherapy, announced today its consolidated results for the 9 months ending September 30, 2012.
The Third Quarter Report 2012 including key events and a selection of consolidated key figures for the 9 months ending September 30, 2012 can be downloaded at:
http://www.bebig.eu/investor_relations/financial_reports/interim_results.html:
http://www.bebig.eu/investor_relations/financial_reports/interim_results.html
Sales for the first three quarters of 2012 reached 21.8 million EUR, compared to 19.6 million EUR in first three quarters of 2011, showing an increase of 11.2%. The main components were revenues generated by the sales of permanent brachytherapy I-125 radiotherapeutic implants as well as revenues from temporary brachytherapy equipment, i.e. HDR equipment using Co-60 (Cobalt 60) and Ir-192 (Iridium 192) sources (also called "afterloaders").
Earnings before interest and taxes (EBIT) have reached 2.1 million EUR in the first three quarters of 2012, versus 2.2 million EUR in the first three quarters of 2011, showing a decrease of 3.6%.
Net profit reached 0.90 million EUR in the first three quarters of 2012, compared to the net profit of 1.04 million EUR in the first three quarters of 2011.
Total equity of the group stood at 40.0 million EUR on September 31, 2012, versus 39.1 million EUR on December 31, 2011.
Eckert & Ziegler BEBIG's management reiterates the statements it made in this year's half year report concerning the company's further development. The management predicts that the positive development will continue in the immediate future.
About Eckert & Ziegler BEBIG
...Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry.
Its core business is the treatment of cancer using brachytherapy, a special form of radiation therapy. Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe. The company headquarters are in Belgium, with a production facility in Germany and subsidiaries throughout Europe and in India. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing of its product line.
The company's products and equipment are intended for use by oncologists, radiologists, urologists, and medical physicists.
Eckert & Ziegler BEBIG employs more than 150 people. The company has been listed on the Euronext stock exchange since April 1997 (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB).
Contact:
Investor Relations
Tel.: +32 64 520 808
Email: ir@bebig.eu:
mailto:ir@bebig.eu
Website: www.bebig.eu:
http://www.bebig.eu/
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Eckert & Ziegler BEBIG via Thomson Reuters ONE
